SynthesisJournal of Crohn's & colitis2025
Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review.
Synthesis in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient-reported outcome measures poorly correlate with objective inflammatory bowel disease activity measures: a systematic review.Journal of Crohn's & colitis · 2025Pooled it
- Metabolite-Related Evidence Linking Metabolic Measures to Patient-Reported Outcomes in Inflammatory Bowel Disease: A Critical Narrative Review.Metabolites · 2026Review
- Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care.Journal of clinical medicine · 2026Review
- The Rectal Stump During and After Subtotal Colectomy for Ulcerative Colitis: A Narrative Review of Surgical Strategies, Medical Management Options, and Cancer Surveillance Recommendations.Journal of clinical medicine · 2026Review
- Explainable random forest-SHAP framework for Montreal phenotype-stratified prediction of one-year complications in Crohn's disease.Frontiers in physiology · 2026Article
- Increase in serum prolactin levels as a potential biomarker in Crohn's disease: a prospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsWe investigated the correlations between patient-reported outcome measures (PROMs) and other measures of inflammatory bowel disease (IBD) activity.
methodsA systematic literature review was performed up to June 2022. Searches were conducted in PubMed, Scopus, and Web of Science. A descriptive analysis was performed. The search protocol was registered in PROSPERO (CRD42022383899).
resultsNineteen studies assessed correlations between PROMs and clinical, endoscopic, and laboratory measures of disease activity in IBD. In Crohn's disease (CD), weak positive correlations were reported for PROMs (eg, the 2 item patient-reported outcome [PRO-2], mobile Health Index [mHI] for CD) and endoscopic scores, more often the Simple Endoscopic Score for CD (SES-CD). In ulcerative colitis (UC), PROMs like PRO-2, the Monitor IBD at Home rectal bleeding item, and the mHI showed weak-to-moderate correlations with the Mayo endoscopic subscore (MES). PROMs also demonstrated limited concordance with laboratory measures such as fecal calprotectin (FCP) and C-reactive protein (CRP) in both CD and UC. The substantial heterogeneity in study designs precluded a structured analysis.
conclusionsAlthough current PROMs offer valuable complementary insights into IBD control from the patient's perspective, they cannot replace objective measures of IBD activity. Future research should focus on refining PROMs and generating composite indices to improve their accuracy and usefulness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.